AN OPEN-LABEL EXTENSION (OLE) STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF AMG 334

Registry ID

20130255

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

AMGEN CANADA INC

Start date

2016-07-08

Last update

2014-04-09

Conditions

• CHRONIC MIGRAINE

Related clinical trials

• A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE ESCALATION AND DOSE FINDING PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF IPN10200 IN THE PREVENTION OF EPISODIC OR CHRONIC MIGRAINE IN ADULTS (MERANTI)
• A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, CLINICAL TRIAL WITH EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF XEOMIN® INJECTIONS FOR THE PREVENTION OF CHRONIC MIGRAINE
• A PHASE 3, MULTICENTER, 12-WEEK, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ATOGEPANT FOR THE PREVENTIVE TREATMENT OF CHRONIC MIGRAINE IN PEDIATRIC SUBJECTS 12 TO 17 YEARS OF AGE
• A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE, PARALLEL-GROUP STUDY WITH EXTENSION PHASE TO EVALUATE THE EFFICACY AND SAFETY OF DYSPORT® FOR THE PREVENTION OF CHRONIC MIGRAINE IN ADULT PARTICIPANTS
• INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF IV EPTINEZUMAB IN ADOLESCENTS (12-17 YEARS) FOR THE PREVENTIVE TREATMENT OF CHRONIC MIGRAINE
• LONG TERM, OPEN LABEL (DOSE BLINDED), EXTENSION STUDY OF EPTINEZUMAB IN CHILDREN AND ADOLESCENTS WITH CHRONIC OR EPISODIC MIGRAINE

View on source registry